Clinical trial • Phase III • Endocrinology
RO7795074 for Type 1 diabetes | Obesity | Overweight
Phase III trial of RO7795074 for Type 1 diabetes | Obesity | Overweight. 32 participants.
Overview
- Trial Therapeutic Area
- Endocrinology
- Trial Disease
- Type 1 diabetes | Obesity | Overweight
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 17-10-2025
- First CTIS Authorization Date
- 01-12-2025
Trial design
Phase III trial in Netherlands.
- Target Sample Size
- 32
- Trial Duration For Participant
- 146
Eligibility
Recruits 32 Vulnerable population selected (isVulnerablePopulationSelected=true). Clinical trial group listed as "Healthy volunteers". No consent/assent handling details provided in the record..
- Vulnerable Population
- Vulnerable population selected (isVulnerablePopulationSelected=true). Clinical trial group listed as "Healthy volunteers". No consent/assent handling details provided in the record.
Recruitment
- Planned Sample Size
- 32
- Recruitment Window Months
- 3
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 32
Netherlands
- Earliest CTIS Part Ii Submission Date
- 25-11-2025
- Latest Decision Or Authorization Date
- 18-12-2025
- Processing Time Days
- 23
- Number Of Sites
- 1
- Number Of Participants
- 32
Sites
- Site Name
- Pharmaceutical Research Associates Group B.V.
- Department Name
- Program Management
- Contact Person Name
- Maria Velinova
- Contact Person Email
- Maria.Velinova@iconplc.com
Sponsor
Primary sponsor
- Full Name
- Genentech Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- RO7795074
Related trials
Other published trials that may interest you.